GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (FRA:GBE) » Definitions » Total Liabilities

Genus (FRA:GBE) Total Liabilities : €558.3 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Genus Total Liabilities?

Genus's Total Liabilities for the quarter that ended in Dec. 2023 was €558.3 Mil.

Genus's quarterly Total Liabilities declined from Dec. 2022 (€522.25 Mil) to Jun. 2023 (€513.13 Mil) but then increased from Jun. 2023 (€513.13 Mil) to Dec. 2023 (€558.33 Mil).

Genus's annual Total Liabilities increased from Jun. 2021 (€412.56 Mil) to Jun. 2022 (€519.37 Mil) but then declined from Jun. 2022 (€519.37 Mil) to Jun. 2023 (€513.13 Mil).


Genus Total Liabilities Historical Data

The historical data trend for Genus's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genus Total Liabilities Chart

Genus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 355.01 401.10 412.56 519.37 513.13

Genus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 458.74 519.37 522.25 513.13 558.33

Genus Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genus's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=171.547+(253.942+79.597
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+8.041)
=513.1

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=1174.145-661.017
=513.1

Genus's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=149.622+(317.584+83.458
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+7.661)
=558.3

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=1223.324-664.999
=558.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genus Total Liabilities Related Terms

Thank you for viewing the detailed overview of Genus's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Genus (FRA:GBE) Business Description

Traded in Other Exchanges
Address
Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.

Genus (FRA:GBE) Headlines

No Headlines